R Egido

Universitat de Lleida, Lérida, Catalonia, Spain

Are you R Egido?

Claim your profile

Publications (25)35.57 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Tophi develop during the most advanced clinical stage of gout, and are usually located on or around the joints. However, unusual skin features caused by intradermal and/or subcutaneous deposition of tophaceous material at locations other than articular regions have been reported. We present the case of a patient with a condition that has been recently termed 'miliarial gout'. which is only the second such case, to our knowledge. A 51-year-old woman, who had a chronic joint disease that had been diagnosed and treated as psoriatic arthritis, presented with multiple asymptomatic, yellowish-white, firm papules (1-3 mm in size) on erythematous areas on the outside of her left leg. On histological examination of a skin biopsy, uric acid crystals were seen in the dermis and subcutis. The patient also had a raised level of serum urate, consistent with a diagnosis of gout. Treatment with allopurinol led to rapid improvement. Intake of corticosteroids and diuretics was a possible triggering factor for the development of cutaneous tophi in this patient.
    Clinical and Experimental Dermatology 08/2013; 38(6):622-5. DOI:10.1111/ced.12084 · 1.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the use of multiple therapeutic strategies, metastatic melanoma remains a challenge for oncologists. Thus, new approaches using combinational treatment may be used to try to improve the prognosis of this disease. In this report, we have analyzed the expression of receptor tyrosine kinases (RTKs) in melanoma specimens and in four metastatic melanoma cell lines. Both melanoma specimens and cell lines expressed RTKs, suggesting that they may represent eventual targets for multitargeted tyrosine kinase inhibitor, Suntinib. Sunitinib reduced the proliferation of two melanoma cell lines (M16 and M17) and increased apoptosis in one of them (M16). Moreover, the two metastatic melanoma cell lines harbored an activated receptor (PDGFRα and VEGFR, respectively), and Sunitinib suppressed the phosphorylation of the RTKs and their downstream targets Akt and ribosomal protein S6, in these two cell lines. Similar results were obtained when either PDGFRα or VEGFR2 expression was silenced by lentiviral-mediated short-hairpin RNA delivery in M16 and M17, respectively. To evaluate the interaction between Sunitinib and Bortezomib, median dose effect analysis using MTT assay was performed, and combination index was calculated. Bortezomib synergistically enhanced the Sunitinib-induced growth arrest in Sunitinib-sensitive cells (combination index < 1). Moreover, LY294002, a PI3K inhibitor, sensitized melanoma cells to Bortezomib treatment, suggesting that downregulation of phospho-Akt by Sunitinib mediates the synergy obtained by Bortezomib + Sunitinib cotreatment. Altogether, our results suggest that melanoma cells harboring an activated RTK may be clinically responsive to pharmacologic RTK inhibition by Sunitinib, and a strategy combining Sunitinib and Bortezomib, may provide therapeutic benefit.
    International Journal of Cancer 02/2012; 130(4):967 - 978. DOI:10.1002/ijc.26096 · 5.01 Impact Factor
  • Source
    Breakthroughs in Melanoma Research, 06/2011; , ISBN: 978-953-307-291-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors have indicated no significant interest with commercial supporters.
    Dermatologic Surgery 11/2010; 36(11):1763-8. DOI:10.1111/j.1524-4725.2010.01746.x · 1.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Somatostatin analogues (SAs) are potential anticancer agents. This study was designed to investigate the expression of somatostatin receptors (SSTRs) in melanoma cells and the effect of two SAs on cell proliferation and viability. Eighteen primary and metastatic human cutaneous melanoma cell lines were treated with octreotide and SOM230. Expression of SSTR1, SSTR2, SSTR3 and SSTR5 was assessed by real-time polymerase chain reaction. Proliferation, viability and cell death were assessed using standard assays. Inhibition was modelled by mixed-effect regression. Melanoma cells expressed one or more SSTR. Both SAs inhibited proliferation of most melanoma cell lines, but inhibition was < 50%. Neither SA affected cell viability or induced cell death. The results suggest that melanoma cell lines express SSTRs. The SAs investigated, under the conditions used in this study, did not, however, significantly inhibit melanoma growth or induce cell death. Novel SAs, combination therapy with SAs and their anti-angiogenic properties should be further investigated.
    The Journal of international medical research 10/2009; 37(6):1813-1822. DOI:10.1177/147323000903700617 · 1.10 Impact Factor
  • Source
    Piel 10/2009; 24(8):458-459. DOI:10.1016/S0213-9251(09)72508-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 58-year-old woman presented with a nodular lesion on the medial part of her left lower eyelid. The lesion had been removed 10 years ago, but showed subsequent recurrence with slow growth. The lesion was again partially removed at another institution prior to presentation. Afterward removal, the persistent lesion had rapid growth. On presentation to us, the lesion showed a clinical appearance that was very similar to a nodular basal cell carcinoma. A pentagonal full-thickness resection biopsy was performed. The pathologic study revealed clusters of tumor cells and some ductal proliferations. Immunohistochemistry demonstrated positive staining for p63, S-100, and smooth muscle actin. No atypia was observed. A diagnosis of pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) was made. The authors conclude that myoepithelioma should be considered in the differential diagnosis of nodular recurrent masses in the eyelids of adults. Definitive diagnosis is possible only after surgical biopsy.
    Ophthalmic Plastic and Reconstructive Surgery 05/2008; 24(3):223-5. DOI:10.1097/IOP.0b013e318171a5ba · 0.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous malignant melanoma is an aggressive type of skin cancer which causes disproportionate mortality in young and middle-aged adults. Once disseminated, melanoma can be considered an incurable disease, highly resistant to standard antineoplastic treatment, such as chemotherapy or radiation therapy. The proteasome represents a novel target for cancer therapy that can potentially be used in melanoma. To assess the effect of four structurally different proteasome inhibitors on human cutaneous melanoma-derived cell lines. Sixteen human cutaneous melanoma-derived cell lines which are original were obtained from patients who were treated by two of the authors. Cells were cultured, exposed to proteasome inhibitors (bortezomib, ALLN, MG-132 and epoxomicin) and then assayed for cell cycle and cell death analyses. Proteasome inhibitors inhibited the in vitro growth of melanoma cells, and this effect was due to a reduction in cell proliferation rate and an induction of both caspase-dependent and caspase-independent cell death. Moreover, release of apoptosis-inducing factor was observed in the presence of the broad-specificity caspase inhibitor BAF (Boc-D-fmk). In addition, the four different proteasome inhibitors induced caspase 2 processing. This study provides information regarding the in vitro effects of proteasome inhibitors on melanoma cell lines, and the molecular mechanisms involved. It also gives support to the future use of such inhibitors in the treatment of patients with melanoma, either administered alone or in combination with other drugs.
    British Journal of Dermatology 04/2008; 158(3):496-504. DOI:10.1111/j.1365-2133.2007.08390.x · 4.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the usefulness of repeat cytological examination of pleural fluid (PF) for diagnosing malignancy as well as the influence of time length between analyses, effusion's size and pleural fluid biochemistries on the diagnostic yield of cytology. Retrospective analysis of 1,427 patients with pleural effusion (PE), including 466 patients with malignant PE. In this latter group, the time length between cytological analysis, the size of the PE, and the biochemical characteristics of PF were recorded. The first cytological analysis had a sensitivity of 48.5%. If this was negative, a second PF specimen was diagnostic in 28.6% of cases, whereas submission of a third PF specimen allowed 10.3% of additional diagnosis. The incidence of positive results depended on the primary tumor (e.g. 66.5% in adenocarcinomas, 30.8% in mesotheliomas), but neither on the time length between cytological analyses nor on the effusion's size. A multivariate analysis showed that a PF to serum glucose ratio </= 0.75 was associated with a higher diagnostic yield of cytology (74 vs. 47%, p < 0.001). At least a second PF specimen should be submitted immediately for cytologic analyis in all PE of unknown cause, when the first analysis is not contributory. To delay this second analysis does not increase diagnostic yield. The percentage of cases in which cytologic study of the PF established the diagnosis of malignant PE depends on the tumor type and on certain PF biochemical characteristics such as the PF to serum glucose ratio.
    Anales de medicina interna (Madrid, Spain: 1984) 04/2008; 25(4):173-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To assess the usefulness of repeat cytological examina - tion of pleural fluid (PF) for diagnosing malignancy as well as the influ - ence of time length between analyses, effusion's size and pleural fluid biochemistries on the diagnostic yield of cytology. Methods: Retrospective analysis of 1,427 patients with pleural effu - sion (PE), including 466 patients with malignant PE. In this latter group, the time length between cytological analysis, the size of the PE, and the biochemical characteristics of PF were recorded. Results: The first cytological analysis had a sensitivity of 48.5%. If this was negative, a second PF specimen was diagnostic in 28.6% of cas - es, whereas submission of a third PF specimen allowed 10.3% of addi - tional diagnosis. The incidence of positive results depended on the pri - mary tumor (e.g. 66.5% in adenocarcinomas, 30.8% in mesotheliomas), but neither on the time length between cytological analyses nor on the effusion's size. A multivariate analysis showed that a PF to serum glu - cose ratio ≤ 0.75 was associated with a higher diagnostic yield of cytol - ogy (74 vs. 47%, p < 0.001). Conclusion: At least a second PF specimen should be submitted immediately for cytologic analyis in all PE of unknown cause, when the first analysis is not contributory. To delay this second analysis does not increase diagnostic yield. The percentage of cases in which cytologic study of the PF established the diagnosis of malignant PE depends on the tumor type and on certain PF biochemical characteristics such as the PF to serum glucose ratio.
    Anales de medicina interna (Madrid, Spain: 1984) 01/2008; 25(4). DOI:10.4321/S0212-71992008000400005
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El melanoma cutáneo es una de las neoplasias cuya incidencia está aumentando más en los últimos años (un 3-8% anual). No obstante, los datos epidemiológicos apuntan a que, en todo el mundo, la mortalidad actual del total de pacientes diagnosticados de melanoma (11%) ha disminuido sensiblemente respecto a la regis-trada en la década de los sesenta (60%). Este hecho se ha atribuido, entre otras causas, a un incremento en el diagnóstico precoz de esta neoplasia y, consecuente-mente, en el tratamiento quirúrgico del tumor primario en las primeras fases de la enfermedad. Sin embargo, apenas se ha avanzado nada en el tratamiento del mela-noma diseminado, extraordinariamente resistente a los tratamientos antineoplásicos convencionales, como la radioterapia o la quimioterapia. La mediana de supervi-vencia de los pacientes con metástasis a distancia es de tan sólo 6-8 meses. Por ello, y por el grupo de edad en el que incide, el melanoma sigue causando una mortalidad desproporcionada en individuos jóvenes o de mediana edad. En Estados Unidos se calcula una pérdida media de 18,6 años de vida potencial por cada persona que muere por melanoma, una de las tasas más altas regis-tradas en personas adultas afectas de cáncer 1 . Todos estos hechos hacen que se investigue intensamen-te en todo el mundo sobre nuevas estrategias terapéuticas aplicables al melanoma diseminado. Entre ellas cabe des-tacar la inmunoterapia, la terapia génica y los tratamientos contra las llamadas «nuevas dianas terapéuticas» 2,3 . Denominamos dianas terapéuticas a moléculas, gene-ralmente proteínas, cuya expresión o sobreexpresión confiere a la célula tumoral el fenotipo que define las neoplasias, es decir, capacidad de crecimiento ilimitado, invasión y metástasis. Consideraremos que una de estas moléculas puede ser una diana terapéutica si somos ca-paces de diseñar fármacos que actúen sobre ella de for-ma específica, en general inhibiendo su función e impi-diendo, por tanto, una o varias de las características celulares de malignidad. La principal ventaja del trata-miento antineoplásico mediante fármacos contra dianas moleculares es la especificidad. Por un lado, los trata-mientos antineoplásicos convencionales actúan de for-ma inespecífica tanto sobre las células neoplásicas como sobre células normales de todos los tipos celula-res, y por ello poseen una gran toxicidad que, como se sabe, se traduce en náuseas, vómitos, alopecia, leucoci-topenia, anemia, trombocitopenia, etc. En cambio, los tratamientos contra dianas moleculares pueden diseñar-se contra moléculas que sólo se manifiesten de forma al-terada en las células neoplásicas y, por tanto, apenas afecten al resto del organismo, con lo que se disminuye los efectos secundarios. Otra ventaja de la especificidad es la de discriminar entre grupos de pacientes aparente-mente iguales. Por ejemplo, actualmente, en el adeno-carcinoma de mama, sólo reciben tratamiento con el nuevo fármaco trastuzumab (Herceptin ®) las pacientes con tumores que tienen activado el oncogén c-erb-B2. En estas pacientes, la proteína codificada por ese gen sería la nueva diana terapéutica 4 .
    Piel 04/2007; 22:205-11. DOI:10.1016/S0213-9251(07)73052-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present the case of a newborn with congenital absence of skin in the anterior part of the left leg that shortly after developed bulla and erosions in hands, feet, ears, buttocks and mouth. The cutaneous biopsy and ultrastructural and immunohistochemical studies showed a subepidermal bulla in the lamina lucida, absence of hemidesmosomes and marked decrease of laminin 5, thus establishing the diagnosis of Bart syndrome associated to the Herlitz form of lethal junctional epidermolysis bullosa. Bart syndrome consists of congenital and localized absence of skin, nail abnormalities and mucoc-cutaneous bullae. It is usually associated to dystrophic epidermolysis bullosa. The Herlitz form of junctional epidermolysis bullosa is a rare variant, usually lethal that is produced by mutations in the genes coding for the anchor protein laminin 5. To our knowledge this is the second case that reports an association between Bart syndrome and lethal junctional epidermolysis bullosa and the first in which the results of immunofluorescence mapping are published.
    Actas Dermo-Sifiliográficas 01/2007; 97(10):658-61.
  • Anales de medicina interna (Madrid, Spain: 1984) 12/2006; 23(11):560-1.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We present the case of a newborn with congenital absence of skin in the anterior part of the left leg that shortly after developed bulla and erosions in hands, feet, ears, buttocks and mouth. The cutaneous biopsy and ultrastructural and immunohistochemical studies showed a subepidermal bulla in the lamina lucida, absence of hemidesmosomes and marked decrease of laminin 5, thus establishing the diagnosis of Bart syndrome associated to the Herlitz form of lethal junctional epidermolysis bullosa. Bart syndrome consists of congenital and localized absence of skin, nail abnormalities and mucoc-cutaneous bullae. It is usually associated to dystrophic epidermolysis bullosa. The Herlitz form of junctional epidermolysis bullosa is a rare variant, usually lethal that is produced by mutations in the genes coding for the anchor protein laminin 5. To our knowledge this is the second case that reports an association between Bart syndrome and lethal junctional epidermolysis bullosa and the first in which the results of immunofluorescence mapping are published.
    Actas Dermo-Sifiliográficas 12/2006; 97(10). DOI:10.1016/S0001-7310(06)73489-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Standard antineoplastic treatment for metastatic melanoma is ineffective in the large majority of patients. Therefore, alternative approaches need to be investigated. STI571 is a new antineoplastic compound, which selectively inhibits the tyrosine kinase activity of ABL, c-Kit and platelet-derived growth factor receptor (PDGFR). Melanoma may express all of these proteins. The aim of this study was to investigate whether STI571 inhibits the in-vitro growth of melanoma cells. Nineteen cell lines were obtained from four primary and 15 metastatic melanomas of cutaneous origin. The percentages of positive cells for the putative targets of STI571 were as follows: ABL, 41-100%; c-Kit, 8-97%; PDGFR-alpha, 41-98%; PDGFR-beta, 51-99%. 3-(4,5-Dimethylthiazol-yl)-2,5-diphenyltetrazolium (MTT) and viability assays showed that STI571 clearly inhibits the proliferation of eight of the 19 (42.1%) cell lines. No relationship could be established between the expression of c-Kit, ABL, PDGFR-alpha or PDGFR-beta and the response of cell lines to STI571. Our study shows, for the first time, an antiproliferative effect of STI571 on human melanoma cell lines of cutaneous origin, raising the possibility of the future clinical use of STI571. The identification of the target of STI571 in human cutaneous melanoma cells would allow the selection of patients who could benefit from this treatment.
    Melanoma Research 05/2006; 16(2):127-35. DOI:10.1097/01.cmr.0000215039.30812.9b · 2.10 Impact Factor
  • Source
    Nephrology Dialysis Transplantation 04/2006; 21(3):789-91. DOI:10.1093/ndt/gfi298 · 3.49 Impact Factor
  • Anales de medicina interna (Madrid, Spain: 1984) 01/2006; 23(11). DOI:10.4321/S0212-71992006001100017
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 4 patients undergoing hemodialysis for chronic renal failure, a transient or persistent, papular and keratotic eruption developed on the trunk and arms. Histologic examination disclosed focal acantholysis with dyskeratosis. The lesions were clinically and histologically indistinguishable from those of Grover's disease. A possible association with Grover's disease and chronic renal failure and/or hemodialysis is postulated. Possible implicated pathogenic mechanisms are discussed. We suggest that Grover's disease should be included in the differential diagnosis of cutaneous eruptions in patients with chronic renal failure.
    Journal of the American Academy of Dermatology 01/2000; 41(6):1029-33. DOI:10.1016/S0190-9622(99)70269-0 · 5.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 40-year-old man and his 6-year-old only son had numerous, firm papulonodular lesions on their faces. Their medical histories were unremarkable and no family consanguinity was recorded. Surgical excision of several lesions was performed on each patient. All the lesions were solid tumors with the characteristic histopathologic features of pilomatricoma. A gastrointestinal radiologic and fibroscopic survey disclosed numerous adenomatous colonic polyps in the father. Additional studies revealed that he also had minor dental abnormalities, a small osteoma on the right mandible, and unilateral, ocular, pigmented retinal macules. The diagnosis of multiple adenomatous colonic polyposis was established only after the well-known association of pilomatricoma-like changes in epidermal cysts in patients with Gardner syndrome was considered. Possibly, multiple familial pilomatricomas could be considered a cutaneous marker of Gardner syndrome.
    Pediatric Dermatology 01/1996; 12(4):331-5. DOI:10.1111/j.1525-1470.1995.tb00195.x · 1.52 Impact Factor
  • Revista Clínica Española 09/1995; 195(8):583-4. · 1.31 Impact Factor

Publication Stats

160 Citations
35.57 Total Impact Points

Institutions

  • 2013
    • Universitat de Lleida
      Lérida, Catalonia, Spain
  • 2006–2012
    • Hospital Universitari Arnau de Vilanova
      Lérida, Catalonia, Spain
  • 1996
    • Hospital de la Santa Creu i Sant Pau
      • Biochemistry Services
      Barcino, Catalonia, Spain
  • 1992–1994
    • Hospital Arnau de Vilanova
      Valenza, Valencia, Spain
    • University of Barcelona
      Barcino, Catalonia, Spain